Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
22.05
+0.82 (3.86%)
At close: Nov 21, 2025, 4:00 PM EST
22.25
+0.20 (0.91%)
After-hours: Nov 21, 2025, 7:53 PM EST
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$382,775
Profits / Employee
-$543,860
Market Cap
2.73B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | 236 | 97 | 69.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RCUS News
- 5 days ago - Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 23 days ago - Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock - Business Wire
- 24 days ago - Arcus Biosciences Announces Commencement of Public Offering of Common Stock - Business Wire
- 26 days ago - Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 5 weeks ago - Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia - Business Wire
- 5 weeks ago - Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets - Seeking Alpha
- 6 weeks ago - Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study - Business Wire
- 6 weeks ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire